S
Sandrine Aspeslagh
Researcher at Université Paris-Saclay
Publications - 13
Citations - 658
Sandrine Aspeslagh is an academic researcher from Université Paris-Saclay. The author has contributed to research in topics: Cancer & Janus kinase 1. The author has an hindex of 10, co-authored 13 publications receiving 452 citations. Previous affiliations of Sandrine Aspeslagh include University of Paris-Sud.
Papers
More filters
Journal ArticleDOI
Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease.
François-Xavier Danlos,Anne-Laure Voisin,Valérie Dyevre,Jean-Marie Michot,Emilie Routier,Laurent Taillade,Stéphane Champiat,Sandrine Aspeslagh,Julien Haroche,Laurence Albiges,Christophe Massard,Nicolas Girard,Stéphane Dalle,Benjamin Besse,Salim Laghouati,Jean-Charles Soria,Christine Mateus,Caroline Robert,Emilie Lanoy,Aurélien Marabelle,Olivier Lambotte +20 more
TL;DR: In patients treated with anti-PD-1 antibody, pre-existing AID was associated with a significantly increased risk of irAEs, and results indicate that cancer treatments withAnti- PD-1 antibodies are just as effective in AID patients as they are in AIDs-free patients.
Journal ArticleDOI
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)☆
Frédéric Bigot,Eduardo Castanon,Capucine Baldini,A. Hollebecque,Alberto Carmona,Sophie Postel-Vinay,Eric Angevin,Jean-Pierre Armand,Vincent Ribrag,Sandrine Aspeslagh,Andrea Varga,Rastislav Bahleda,Jessica Menis,Anas Gazzah,Jean-Marie Michot,Aurélien Marabelle,Jean-Charles Soria,Christophe Massard +17 more
TL;DR: Traditional prognostic variables included in the RMH score may be suboptimal to determine patient's prognosis in ICT phase I trials, and the Gustave Roussy Immune Score, based on albumin, LDH and NLR, allows a better selection of patients for ICT phases I trials.
Journal ArticleDOI
Long-Term Survival in Patients Responding to Anti–PD-1/PD-L1 Therapy and Disease Outcome upon Treatment Discontinuation
Marie-Léa Gauci,Emilie Lanoy,Stéphane Champiat,Stéphane Champiat,Caroline Caramella,Samy Ammari,Sandrine Aspeslagh,Andrea Varga,Capucine Baldini,Rastilav Bahleda,Anas Gazzah,Jean-Marie Michot,Sophie Postel-Vinay,Eric Angevin,Vincent Ribrag,Antoine Hollebecque,Jean-Charles Soria,Caroline Robert,Christophe Massard,Aurélien Marabelle +19 more
TL;DR: The results are in favor of evaluating patient stratification strategies and intensification of treatments when tumor lesions of a partial responder to immunotherapy stop improving, and a striking difference in OS is found between these two types of responses.
Journal ArticleDOI
Rapid and objective CT scan prognostic scoring identifies metastatic patients with long-term clinical benefit on anti-PD-1/-L1 therapy
Laurent Dercle,Laurent Dercle,Samy Ammari,Stéphane Champiat,Christophe Massard,Charles Ferté,Lokmane Taihi,Romain-David Seban,Sandrine Aspeslagh,Linda Mahjoubi,Nyam Kamsu-Kom,Caroline Robert,Aurélien Marabelle,Aurélien Marabelle,Martin Schlumberger,Martin Schlumberger,Jean-Charles Soria,Sophie Postel-Vinay +17 more
TL;DR: Objective and rapid-risk scoring based on three CT scan parameters allows identifying patients with prolonged OS on anti-PD-1/-L1 therapy, independently from conventional clinical-biological prognostic scores.
Journal ArticleDOI
Onset of connective tissue disease following anti-PD1/PD-L1 cancer immunotherapy
Sébastien Le Burel,Stéphane Champiat,Stéphane Champiat,Emilie Routier,Sandrine Aspeslagh,Laurence Albiges,Tali-Anne Szwebel,Jean-Marie Michot,Pascale Chrétien,Xavier Mariette,Anne-Laure Voisin,Olivier Lambotte +11 more
TL;DR: Of the 447 patients supervised in the REISAMIC registry, three have developed CTD: two cases of Sjogren's syndrome and one case of cryoglobulinemic vasculitis as a complication of suspected Sjogsen's syndrome.